上海
EGFR突變NSCLC治療格局已被改寫，開啟長生存時代。
*以下內容僅供醫療衛生專業人士瀏覽。
參考文獻：
[1] Cho BC, Lu S, Felip E, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024;391(16):1486-1498.
[2]Cho BC, Lu S, Felip E, et al. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2025 Sep 7.
[3]Lu S, et al. Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment Among Asian Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): MARIPOSA Subgroup Analysis. 2023 ESMO Asia. LBA10.
[4]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines?) Non-Small Cell Lung Cancer. Version 2. 2026.
[5]中國臨床腫瘤學會（CSCO）非小細胞肺癌診療指南（2025年）.
[6]Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024;35(1):77-90.
[7]Shih JY, Wang J, Wang Y, et al. Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis. 2023 ESMO Asia. LBA11.
[8]Califano R, Passaro A, Tan JL, et al. Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Outcomes by osimertinib resistance mechanisms in MARIPOSA-2. 2025 ASCO. Abstract 8639.
[9]Reck M, et al. Amivantamab Plus Chemotherapy vs Chemotherapy in EGFR-mutant Advanced NSCLC After Progression on Osimertinib: A Post-progression Analysis of MARIPOSA-2. ELCC Congress 2024, 3MO.
[10]Zhou CC, Tang KJ, Cho BC, et al. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051.
[11]Zhou CC, Tang KJ, Liu B, et al. Amivantamab Plus Chemotherapy vs Chemotherapy as a First-line Treatment Among Asian Patients With EGFR Exon 20 Insertion-mutated Advanced Non-small Cell Lung Cancer (NSCLC): PAPILLON Subgroup Analysis. 2023 ESMO Asia. 513MO.
[12]Felip E, Shu C, Aguilar A, et al. Amivantamab Plus Chemotherapy vs Chemotherapy as First-Line Treatment in EGFR Exon 20 Insertion–mutated Advanced NSCLC: Analysis of PostProgression Endpoints From PAPILLON. 2024 ELCC. 2MO.
審批編碼：CP-558510
批準分發日期：12/18/2025
有效期：12/18/2026
*“醫學界”力求所發表內容專業、可靠，但不對內容的準確性做出承諾；請相關各方在采用或以此作為決策依據時另行核查。
特別聲明：以上內容(如有圖片或視頻亦包括在內)為自媒體平臺“網易號”用戶上傳并發布，本平臺僅提供信息存儲服務。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
